Prognosis
Booster Dose Slashes Rates of Covid Infection in Israeli Study
- Results of short-term study seen supporting Biden booster plan
- FDA advisory panel preparing to evaluate boosters Friday
This article is for subscribers only.
A third dose of the Pfizer Inc.-BioNTech SE Covid vaccine can dramatically reduce rates of Covid-related illness in people 60 and older, according to data from a short-term study in Israel.
Starting 12 days after the extra dose, confirmed infection rates were 11 times lower in the booster group compared with a group that got the standard two doses, the analysis released Wednesday by the New England Journal of Medicine found. Rates of severe illness were almost 20 times lower in the booster group.